I
n patients with symptomatic carotid stenosis, cerebral embol ization from the carotid plaque is associated with increased risk of stroke. 1 Transcranial Doppler (TCD) detected cerebral microemboli are biomarkers of risk of stroke syndromes in symptomatic carotid stenosis and after carotid endarterectomy (CEA). 2 There is no consensus on which antiplatelet therapy is most effective in abolishing microemboli. Pharmacological agents effective in acute coronary syndromes could be benefi cial in carotid disease to prevent stroke syndromes. 2 We aimed to compare effects of the glycoprotein IIb/IIIa receptor antagonist tirofiban 3, 4 with the antithrombotic poly saccharide dextran40 in patients with high microembolic rates after CEA.
Subjects and Methods
Our Carotid Registry comprises 576 patients who underwent elective CEA 5 between August 2000 and December 2010 and were monitored by TCD 6 after surgery. It has been our unit policy to use TCDdirected intravenous antiplatelet agents in all patients with microemboli sig nals (MES) rate ≥50 hour −1 . Prior to 2002, we used TCD dextran40 and after that date we used tirofiban. We report retrospectively on 74 patients with postsurgery MES rate ≥50 hour −1 and given either dextran40 (n=34) or tirofiban (n=40) and on 54 patients with MES rate <50 hour −1 resolving spontaneously. All patients had preopera tive single or dual oral antiplatelet treatment (aspirin+clopidogrel or aspirin+dipyridamole-tirofiban: single n=32, dual n=8; dextran: single n=32, dual n=2; for patients with spontaneous MES resolution: single n=36, dual n=18).
Immediately patients recovered from anesthesia, TCD 6 (PC Dop 842, SciMed, Bristol, UK) was used to monitor the middle cerebral artery ipsilateral to the operated artery, or in patients lacking an acoustic temporal window, transorbital monitoring of the carotid siphon was used. 6 The microemboli 7 rate was calculated at 15minute intervals. We added treatment with tirofiban 8 
Results
The demographic profile, cardiovascular risk factor (Table  1) , and preoperative blood results were similar in the 3 groups, other than family history of cardiovascular disease being more common in patients with MES on tirofiban, or with spontaneous resolution.
MES Kinetics After CEA
In view of group differences in preoperative anti platelet treatment, we analyzed data both for all subjects and separately for those only on single antiplatelet treatment preoperatively. 
Time to Resolution
Patients receiving tirofiban achieved earlier complete MES resolution compared with dextran40 (Log Rank [Mantel Cox], 2way P<0.001) ( Table 2) .
Complications

Twenty-Four Hours Postsurgery
In 5 patients who developed transient ischemic attack or stroke, despite dextran40, the MES rate was initially 60% higher and remained markedly raised during infusion ( Figure) , compared with patients in whom MES resolved uneventfully following dextran40 (n=29).
Thirty Days Postsurgery
Ischemic stroke occurred in 1 tirofibantreated patient 1 week after surgery. Two fatal myocardial infarctions occurred in dextran40treated patients, 1 fatal myocardial infarction in a tirofibantreated patient, and 1 fatal myocardial infarction in a patient who did not receive rescue antiplatelet treatment. One tirofibantreated patient died from intracerebral hemorrhage 4 days postsurgery. In the immediate postoperative phase, this patient had received an intravenous nitrate infusion for hypertension and a hyperperfusion syndrome. Platelet count was normal before the hemorrhagic event.
Late Events (30 Days to 1 Year)
One fatal myocardial infarction and 1 intracerebral hemor rhage occurred in different patients in the spontaneous resolu tion group.
Discussion
Despite antiplatelet therapy before CEA, patients may develop microemboli acutely postsurgery and so be at marked increased risk of postoperative stroke. 9 Our results showed that in patients refractory to single or dual antiplatelet treatment, compared with dextran40, 5 tirofi ban resulted in a large reduction in halflife MES and time to MES resolution. This advantage of tirofiban was not explained by differences in cardiovascular risk factor burden (Table  1) . Until this study, it had not been clear whether tirofiban would have benefits over dextran40 treatment. Tirofiban also provides an effective treatment option in patients resistant to aspirin and clopidogrel. 12 No patients had transient ischemic attack or acute stroke while on tirofiban, whereas 5 of 34 patients had adverse neuro logical outcomes, despite dextran40. In our study, the tirofi banassociated bleeding rates were comparable with a trial of tirofiban in the setting of acute stroke. 4 
Conclusions
Our report provides support for randomized controlled trials of the clinical and costeffectiveness of tirofiban in reducing stroke incidence after CEA.
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